EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Efficient delivery of Temozolomide using ultrasmall large-pore silica nanoparticles for glioblastoma

Taskeen Iqbal Janjua, Yuxue Cao, Aria Ahmed-Cox, Aun Raza, Md Moniruzzaman, Dewan Taslima Akhter, Nicholas L Fletcher, Maria Kavallaris, Kristofer J Thurecht, Amirali Popat

Journal of Controlled Release · 2023-05 · 357 · 161-174

DOI: 10.1016/j.jconrel.2023.03.040 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Controlled Release, 2023-05. Verfasst von Taskeen Iqbal Janjua und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, The University of Queensland, Brisbane, QLD 4102, Australia. Hauptthemen laut MEDLINE: Glioblastoma, Nanoparticles, Brain Neoplasms. Die Arbeit wurde bisher 74-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Cancer Australia, Cancer Institute NSW, University of Queensland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The prognosis of brain cancers such as glioblastoma remains poor despite numerous advancements in the field of neuro-oncology. The presence of the blood brain barrier (BBB) along with the highly invasive and aggressive nature of glioblastoma presents a difficult challenge for developing effective therapies. Temozolomide (TMZ) is a first line agent used in the clinic for glioblastoma and it has been useful in increasing patient survival rates. However, TMZ suffers from issues related to its pharmacokinetics, such as a short plasma half-life (2 h), is subjected to P-gp efflux, and has limited extravasation from blood to brain (∼20%). It has been postulated that reducing its efflux and increasing glioblastoma tissue exposure to TMZ could prove useful in treating glioblastoma and preventing tumour recurrence. Herein, ultra-small, large pore silica nanoparticles (USLP) have been loaded with TMZ, surface PEGlyated to reduce efflux and decorated with the cascade targeting protein lactoferrin for efficient uptake across the BBB and into glioblastoma. Our results demonstrate that USLP improves permeability of BBB in vitro as evidenced using a transwell model which mimics endothelial tight junctions with permeation being enhanced using PEGylated particles. Data from TMZ loaded USLP in vitro transwell BBB model also suggests that the USLP formulations can significantly reduce the efflux ratio of TMZ. In vitro apoptosis studies on glioblastoma cell lines U87 and GL261 were conducted which showed an improvement in TMZ induced glioblastoma apoptosis with USLP formulations compared to pure TMZ. Finally, a proof-of-concept preclinical mouse study demonstrated that when given intravenously at 50 mg/kg, USLP particles showed accumulation in the brain within a few hours without any obvious pathophysiological changes in vital organs as assessed via histology. Overall, the data suggests our innovative delivery system is efficient in extravasation from blood and permeating the BBB and has potential to improve efficacy of TMZ in glioblastoma therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaNanoparticlesBrain NeoplasmsMiceAnimalsTemozolomideCell Line, TumorBrainAntineoplastic Agents, Alkylating

Stichwörter der Autor:innen

3D glioblastoma modelBlood brain barrierBrain imagingGlioblastomaLactoferrinLarge poreMesoporous silicaOptical imagingSilica functionalisationTargeted drug deliveryTemozolomideUltra-small nanoparticle

Substanzen

TemozolomideAntineoplastic Agents, Alkylating

Autor:innen und Institutionen

  • School of Pharmacy, The University of Queensland, Brisbane, QLD 4102, Australia.
  • Children's Cancer Institute, Lowy Cancer Research Centre, UNSW Sydney, Sydney, NSW 2052, Australia; School of Clinical Medicine, UNSW Medicine & Health, UNSW Sydney, Sydney, NSW 2052, Australia; Australian Centre for Na…
  • School of Pharmacy, The University of Queensland, Brisbane, QLD 4102, Australia; Mater Research Institute -The University of Queensland, Translational Research Institute, Woolloongabba, Brisbane, QLD 4102, Australia.
  • Centre for Advanced Imaging, Australian Institute for Bioengineering and Nanotechnology, University of Queensland, Brisbane, QLD 4072, Australia.
  • Centre for Advanced Imaging, Australian Institute for Bioengineering and Nanotechnology, University of Queensland, Brisbane, QLD 4072, Australia; ARC Training Centre for Innovation in Biomedical Imaging Technologies, Un…
  • School of Pharmacy, The University of Queensland, Brisbane, QLD 4102, Australia; Mater Research Institute -The University of Queensland, Translational Research Institute, Woolloongabba, Brisbane, QLD 4102, Australia. El…

Förderung

  • Cancer Australia
  • Cancer Institute NSW
  • University of Queensland
  • Tour de Cure
  • Australian Research Council

Zitieren

APA

Janjua, T. I., Cao, Y., Ahmed-Cox, A., Raza, A., Moniruzzaman, M., Akhter, D. T., Fletcher, N. L., Kavallaris, M., Thurecht, K. J., & Popat, A. (2023). Efficient delivery of Temozolomide using ultrasmall large-pore silica nanoparticles for glioblastoma. Journal of Controlled Release, 357, 161-174. https://doi.org/10.1016/j.jconrel.2023.03.040

Vancouver

Janjua TI, Cao Y, Ahmed-Cox A, Raza A, Moniruzzaman M, Akhter DT, et al. Efficient delivery of Temozolomide using ultrasmall large-pore silica nanoparticles for glioblastoma. Journal of Controlled Release. 2023;357:161-174. doi:10.1016/j.jconrel.2023.03.040

BibTeX
@article{Janjua2023,
  author = {Janjua, Taskeen Iqbal and Cao, Yuxue and Ahmed-Cox, Aria and Raza, Aun and Moniruzzaman, Md and Akhter, Dewan Taslima and Fletcher, Nicholas L and Kavallaris, Maria and Thurecht, Kristofer J and Popat, Amirali},
  title = {Efficient delivery of Temozolomide using ultrasmall large-pore silica nanoparticles for glioblastoma},
  journal = {Journal of Controlled Release},
  year = {2023},
  volume = {357},
  pages = {161--174},
  doi = {10.1016/j.jconrel.2023.03.040}
}
Kostenlos starten →